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Molecular Dynamics of the Dengue Virus NS3/NS2B Protease in Presence
of Inhibitor or Substrate
Maria Carolina P. Lima, Gustavo de Miranda Seabra.
Dept. Quı´mica Fundamental, UFPE, Recife, Brazil.
Dengue is a neglected tropical disease affecting millions of people, and may lead
to death. Brazil is the country with the highest number of dengue and dengue
hemorrhagic fever (D/DHF) cases combined.[1] However, recent news show
that dengue virus reaches areas that had not been hit earlier as the Madeira Island
(Portugal) [2], Florida (United States) [3], and in New Caledonia (Oceania) [4].
There are no specific medicines for the treatment of D/DHF and, once infected,
the WHO recommendations are limited to observation and symptomatic treat-
ment. Recent efforts have revealed a series of proteins essential to the dengue
virus’s life cycle, which may be used as targets for new medicines. [5].
The objective of this study is to understand the mechanism of action of the
nonstructural protein NS3 protease complexed with the cofactor NS2b (NS3/
NS2b), responsible for cleaving the viral polyprotein during the virus replica-
tion step, and understanding of interaction of this protein with its substrate and
inhibitor through molecular dynamics study.
We will be present molecular dynamics simulations of the NS3/NS2b complex
alone, in the presence of the substrate (Ala-Gly-Arg-Lys-Ser-Ile) or an inhibitor
(Bzo-Nle-Lys-Arg-Arg-H) in the active site, as well as hybrid QM/MM simu-
lations for understanding the enzymatic mechanism.
1. World Health Organization. Drug for Neglected Diseases Initiative, 2009.
http://www.dndi.org/. [06/23/2009];
2. http://www.who.int/ith/updates/20121012/en/ [12/10/2012]
3. http://edition.cnn.com/2013/08/27/health/florida-dengue/index.html [27/08/
2013]
4. http://newcaledoniatoday.wordpress.com/2013/04/06/150-contract-dengue-
fever-a-day-in-new-caledonia/ [06/04/2013]
5. Paul Erbel, Nikolaus Schiering, Allan D’Arcy, Martin Renatus, Markus
Kroemer, Siew Pheng Lim, Zheng Yin, Thomas H. Keller, Subhash G.
Vasudevan, and Ulrich Hommel, Nat. Struct. Mol. Biol. 13, 372-373.
Support: CAPES, FACEPE.
1328-Pos Board B58
Dynamical Network in HIV-1 Protease and its Mutants: Implications on
Drug Resistance
Rajeswari Appathurai, Sanjib Senapati.
Department of Biotechnology, Indian Institute of Technology Madras,
Chennai, India.
Drugs targeting HIV protease have long been used in AIDS therapy. However,
emergence of multi-drug resistance, due to active and non-active site mutations,
intensifies the need to understand the drug resistance mechanism of the enzyme.
Here, we employ molecular dynamics (MD) simulations and network analyses
to unravel the drug resistance mechanisms. Results from MD simulations sug-
gest that the mutants modulate either the ligand binding envelop in the active
site or the dynamics of flaps in HIV-1 protease.While themutations at the active
site or flap region account for drug resistance directly, the mechanism of allo-
steric mutations could not be explained. Network analyses show that the allo-
steric mutations affect the functional sites by modulating the stress centrality.
Stress interference data ascribe the residues 71, 90 and 93 as the active site mod-
ulators and 15, 20 and 36 as the flap modulators. The integrity of the global
network, however, was not affected by deletion of the mutant-prone nodes, indi-
cating that the function of HIV-1 protease is preserved.
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Understanding the Molecular Mechanism of Synergistic Inhibition in the
Hepatitis C Virus (HCV) Polymerase Using Molecular Dynamics Simula-
tions and Free Energy Calculations
Jodian A. Brown, Ian F. Thorpe.
University of Maryland Baltimore County, Baltimore, MD, USA.
The Hepatitis C Virus (HCV) affects close to 200 million globally. A major
challenge in treating this infection is the emergence of resistance to current
treatment regimens. An approach to reducing the rate of drug resistance is to
increase the inhibitory effects of allosteric inhibitors by using them in combi-
nation to target the HCV polymerase (NS5B). Although recent biochemical
studies show the use of multiple allosteric inhibitors has a synergistic inhibitory
effect on NS5B, the molecular mechanisms by which this synergistic inhibition
occurs still have not been clearly elucidated. To garner insight into the
mechanism of synergistic inhibition of NS5B, we employ conventional and
temperature accelerated molecular dynamics simulations of the enzyme simul-
taneously bound to two allosteric ligands. In concert with covariance and prin-
cipal component analyses, data from the simulations allow us to comparespecific structural and dynamic properties of the free and ligand-bound protein.
Results thus far suggest that different allosteric ligands induce distinct protein
conformations. Furthermore, when two ligands are present we observe that one
inhibitor has a dominant impact in determining protein conformation. We have
also carried out free energy calculations to understand differences in binding
free energy that arise when one or both inhibitors are bound to NS5B. Under-
standing the molecular mechanism that mediate synergistic inhibition in NS5B
may allow us to optimize the inhibitory activity of these compounds against the
enzyme. In addition, these studies can provide fundamental insights into how
ligand binding regulates protein function. Such information has direct applica-
tions in the areas of drug discovery, regulation of metabolic pathways and other
signal transduction processes.
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Regulatory Elements of HCV NS5B Polymerase - b -Loop and C-Terminal
Tail - are Required for Activity of Allosteric Thumb Site II Inhibitors
Anita Niedziela-Majka1, Sarah E. Boyce1, Neeraj Tirunagari1, Jason Perry2,
Melanie Wong1, Elaine Kan1, Leanna Lagpacan1, Ona Barauskas1,
Magdeleine Hung1, Martijn Fenaux1, Todd Appleby2, William J. Watkins3,
Uli Schmitz2, Roman Sakowicz1.
1Biology, Gilead Sciences Inc., Foster City, CA, USA, 2Structural Chemistry,
Gilead Sciences Inc., Foster City, CA, USA, 3Medicinal Chemistry, Gilead
Sciences Inc., Foster City, CA, USA.
Hepatitis C virus (HCV) chronically infects close to 3% of the world’s popula-
tion, with 30% of carriers expected to develop serious liver-related diseases,
including hepatocellular carcinoma. There is an ongoing effort to develop novel
antivirals to improve the therapeutic outcome of anti-HCV treatment.
We explore the mechanism of action of nonnucleotide inhibitors (NNIs) of
HCV replication that bind to the thumb site II pocket on NS5B polymerase,
exemplified by GS-9669 which is in phase II clinical trials. Despite a wealth
of enzymatic and structural information regarding NS5B it is not fully under-
stood how binding at this remote pocket inhibits the active site. Stabilization
of the closed, inactive enzyme conformation has been suggested, although it
has not been described on the mechanistic level.
We employed a combination of enzyme activity, direct binding, and calori-
metric studies with GS-9669 and other classes of NNIs and several truncation
mutants of NS5B that disrupt critical interactions at the interface of the thumb
domain, b-loop and C-terminus. Our studies demonstrated unique binding and
inhibition profiles for each NNIs. An intact interface between the b-loop and
the C-terminus is critical for inhibitory potency of thumb site II NNIs, although
both elements are dispensable for binding. In addition, calorimetric studies re-
vealed the pivotal role of both regulatory elements in communication between
polymerase domains. We postulate that binding at the thumb site II pocket
locks the entire NS5B in an enzymatically inactive, closed conformation.
This stabilization of the closed conformation is a consequence of the commu-
nication between the binding pocket on the thumb domain and other domains of
polymerase that is mediated by the interactions between two key regulatory
elements: the b-loop and the C-terminal tail.
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Computational Thrombin Inhibitor Optimization
Vytautas Gapsys, Bert de Groot.
Max Planck Institute for Biophysical Chemistry, Goettingen, Germany.
Of the plethora of computational methods for the estimation of binding free en-
ergies, molecular dynamics based alchemical approaches provide remarkable
accuracy at an affordable computational cost. The computationally less expen-
sive empirical ligand and structure based methods require training a predictive
model to yield accurate free energy estimates. In the current study we utilized a
combinatorial chemistry library and combined the chemoinformatic and
alchemical approaches to optimize a set of known thrombin inhibitors. A
confirmed ligand scaffold (D-Phe-Pro) was selected as a basis for modifica-
tions. Prior to designing new compounds, we verified the non-equilibrium
alchemical free energy calculation setup on a set of inhibitors with experimen-
tally measured binding affinities. Afterwards, a combinatorial chemistry library
was constructed by modifying substituents at the ortho, meta and para positions
on a benzene ring facing the S1 thrombin pocket. Navigation in the library was
guided by training the Partial Least Squares based regression models using to-
pological, structural, physicochemical descriptors and COMFA-like coordi-
nates of the molecular electrostatic surfaces. The predicted potential binders
were subjected to the alchemical free energy calculations, and, subsequently,
the obtained estimates were used to update the regression models and improve
prediction accuracy. Few iterations sufficed to reach convergence towards
stronger binders, several of which were predicted to have a higher binding af-
finity than the strongest inhibitors in the initial compound set. While the newly
identified ligands are to be validated in an ITC experiment, the computational
workflow utilizing chemoinformatic approaches for navigation in a
Monday, February 17, 2014 263acombinatorial chemistry library and first principles based alchemical calcula-
tions for accurate free energy estimates appears to be a powerful approach
for ligand optimization.
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Probing the Ligand BindingMechanism ofMnk Inhibitors by Docking and
Molecular Dynamics Simulations
Srinivasaraghavan kannan1,2, Anders Poulsen2, Haiyan Yang2,
Melvyn Ho2, May Ann2, Lohitha Rao Chennamaneni3, Jeffrey Hill2,
Chandra S. Verma1, Kassoum Nacro2.
1Bioinformatics Institute, Singapore, Singapore, 2Experimental Therapeutics
Centre, Singapore, Singapore, 3Institute of Chemical and Engineering
Sciences, Singapore, Singapore.
Mitogen-activated protein kinases-interacting kinases 1 and 2 (MNK1 and
MNK2) are Ser/Thr kinases belongs to the group of Ca2þ/calmodulin-depen-
dent kinases (CaMK) that phosphorylate Eukaryotic initiation factor 4E
(eIF4E) [Luc Furic.,et. al., PNAS, 2010, 107 (32):14134-14139] on Ser-209.
Overexpression of eIF4E has been associated with tumoregenicity and studies
have indicated that eIF4E phosphorylation is oncogenic [Jinqiang Hou. et. al.,
Oncotarget, 2012, 3:118-131]. Therefore, Mnk1/2 inhibitors could be effective
therapeutic agents for the treatment of cancers driven by an overexpression of
phosphorylated eIF4E. In the current study we have carried out molecular
docking combined with molecular dynamics simulations to study the interac-
tion between ligand and Mnk1/2 kinase catalytic domains. Three dimensional
structures of both Mnk1 and Mnk2 were built using comparative modeling
methods. A series of Mnk kinase inhibitors were docked to the ensemble of
representative structures extracted from a clustering analysis of the MD simu-
lations. The predicted bound conformations were further studied in explicit sol-
vent by MD simulations. Our combined computation approach identified key
residues that are important for the protein - inhibitor interactions, provides
detailed understanding of the mechanism of these kinds of inhibitors and will
be useful for the rational design of Mnk inhibitors.
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Development of Novel Xanthine Oxidase Inhibitors with Radical Scav-
enging Properties for the Prevention of Reperfusion Injuries
Stefan Paula, Taylor Kidd, Emily Hofmann, Rebekka Meeks, Reid Kline,
Thuy Do, Timothy Dunn, Lili Ma.
Chemistry, Northern Kentucky University, Highland Heights, KY, USA.
Reperfusion injuries can cause severe damage in hypoxic tissue after the
blockage of oxygen supply has been relieved. The condition frequently occurs
after ischemic events or surgery and is caused by a combination of inflammation
and the generation of harmful reactive oxygen species (ROS). In an effort to gain
access to agents capable of combating the damaging effects of ROS, we devel-
oped compounds with dual properties capable of preventing the generation of
ROS and of absorbing ROS already formed. By combining two beneficial prop-
erties in a single molecule, we expected these compounds to bemore flexible and
effective than those that feature only one of the two activities. Based on the scaf-
folds of the natural products chalcone and caffeic acid phenethyl ester (CAPE),
we synthesized and tested a selection of compounds capable of inhibiting the
enzyme xanthine oxidase (XO), a major source of ROS production, and of
absorbing radicals. Assays employed in this study measured inhibitory potency
against XO activity, radical scavenging ability, and the capacity to increase
cell viability under oxidative stress. In addition, computational docking was per-
formed to elucidate XO/inhibitor interactions at the molecular level. Structure-
activity relationships were established that identified correlations between
molecular structure and the two bioactivities under investigation and that can
guide the future synthesis of materials with improved properties.
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Data Mining the Pdb: Phosphorylation Can Directly Interfere with Drug
Binding
Kyle P. Smith, Kathleen M. Gifford, Julian L. Klosowiak, Sarah E. Rice.
Cell & Molecular Biology, Northwestern University, Chicago, IL, USA.
Asmany as 30%of all proteins are phosphorylated. Protein kinases play a central
role in controlling cell proliferation, differentiation, cell cycle progression, and
angiogenesis - processes which frequently become dysregulated during carcino-
genic transformation. Many experimental therapeutics are developed using puri-
fied protein and may be less effective against targets that are post-translationally
modified in vivo. To test whether protein phosphorylation may decrease drug
binding and increase resistance, we examined 310 unique drug-bound protein
structures mapped from the DrugBank database to the Protein Data Bank. We
cross-referenced the sites with recorded phosphorylation sites found in the Phos-
phoSitePlus database. "Hits" are defined as target proteins that have phosphory-
lated residues within 12 A˚ of their drug binding sites. For these proteins,
phosphorylation could directly interfere with drug binding in vivo. The hits fellinto two classes. Class I hits are targets for which the drug compound competes
with natural substrate in the active site. The phosphorylation site is also in the
active site, and phosphorylation results in inactivation of the protein. One would
not expect a large reduction in drug efficacy for these proteins, as phosphorylation
simultaneously causes drug resistance and inactivates the protein target. ForClass
II hits, the drug compounds bind to allosteric sites outside the active site of the
target protein, and the documented phosphorylation either activates the target
or onlymoderately decreases its activity.Wehypothesize thatClass II compounds
aremore likely to encounter resistancewhen used as therapy, especially in cancer
where there are larger populations of aberrantly phosphorylated proteins.
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Effect of Natural Product Extracts on Lipoxygenase, Cyclooxygenase, and
Protein Tyrosine Phosphatase 1b
Magdalena M. Siodlak, Sharada T. Buddha.
Chemistry, Saint Xavier University, Chicago, IL, USA.
The purpose of this research project is to examine the inhibition of enzymes linked
to inflammation andassociateddiseasesbyplants traditionallyas anti-inflammatory
medicines: Tussilago farfara, Grindelia squarrosa, and Uritca dioica.
Arachidonic acid is metabolized in the body through two main metabolic path-
ways with the enzymes: cyclooxygenases (COX) and lipoxygenases (LOX).
Elevated levels of prostanoids and leukotrienes, products of the two respective
pathways, have been linked to inflammatory diseases. Finding a dual inhibitor
of COX and LOX is promising in preventing the inflammation and diseases that
are linked to the overproduction of both pathways while minimizing the side
effects associated with inhibition of individual pathways.
Furthermore, the enzyme protein tyrosine phosphatase 1b (PTP1b) is linked be-
tween inflammation and metabolic disease through the leptin receptor-associated
Janus Kinase (JAK). PTP1b is a negative regulator of insulin and leptin receptors
thus being explored as a possible therapeutic for type II diabetes and obesity.
Crude methanolic extracts of Tussilago farfara, Grindelia squarrosa, and
Urtica dioica were taken to approximate the plants’ components released in
the body upon consumption. The bioactivities of the standardized extracts
were then determined using enzymatic assay kits for COX I and II, LOX,
and PTP1b. T. farfara is the strongest LOX inhibitor at 60% inhibition of
15-LOX, followed by U. dioica and G. squarrosa at 45% and 39%, respec-
tively. Studies for COX I and II as well as PTP1b inhibition are ongoing,
and the results will be presented.
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Structure-Thermodynamics Correlations of Fluorinated Benzensulfona-
mides as Inhibitors of Human Carbonic Anhydrases
Daumantas Matulis, Joana Gylyt^, Asta Zubrien^, Virginija Dudutien^,
Alexey Smirnov, Lena Manakova, Saulius Grazulis.
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The carbonic anhydrases (CA) are established as therapeutic targets [1]. There
are 12 catalytically active CA isozymes in human body. At least 30 CA sulfon-
amide inhibitors have been used as drugs to treat glaucoma, epileptic seizures,
altitude sickness, and as diuretics. However, most of them exhibit poor selec-
tivity towards target isozymes and result in various side effects.
In this work, a class of 4-substituted-2,3,5,6-tetrafluorobenzensulfonamides as
inhibitors of CA is reported. Crystal structures of CAII, CAXII and CAXIII
bound with the fluorinated compounds were solved and provided structural de-
tails of inhibitor binding. The binding affinity to carbonic anhydrases I, II, VII,
XII and XIII was measured by isothermal titration calorimetry and the fluores-
cent thermal shift assay, and inhibition was determined by stopped-flow CO2
hydration assay. The combined use of these methods has provided a detailed
picture of protein-ligand interactions. Experimentally obtained binding data
usually depends on various factors including temperature, pH, buffer, etc. In
this study, we present intrinsic parameters of binding that are independent of
experimental conditions. Structure-thermodynamics correlations were studied
using intrinsic parameters. All used biophysical methods have confirmed that
fluorinated sulfonamides bound stronger to CA than non-fluorinated, because
of the presence of electronegative substituents that decrease the pKa of sulfon-
amide group and this correlates with an increase in the CA inhibitory properties
[2]. A large group of fluorinated compounds possessed nanomolar affinity for
selected CAs and several of them were selective towards CAI.
1337-Pos Board B67
An Asymmetric Pattern in Binding of Prostaglandin Endoperoxide H Syn-
thases to their Inhibitors and its Implications for Enzyme Catalysis and
Allosteric Regulation
Inseok Song.
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Proteins experience some conformational changes upon ligand bindings and their
effects on protein functions are displayed in variousways. Crystallographic data of
